menu
    • menu
    [{"orgOrder":0,"company":"Stayble Therapeutics","sponsor":"Cromsource | Antaros Medical | Viedoc","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lactic Acid","moa":"Bifunctional protein PutA; NimA-related protein","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Stayble Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stayble Therapeutics \/ Cromsource | Antaros Medical | Viedoc","highestDevelopmentStatusID":"6","companyTruncated":"Stayble Therapeutics \/ Cromsource | Antaros Medical | Viedoc"},{"orgOrder":0,"company":"eXIthera Pharmaceutical","sponsor":"IDT CMAX Clinical Trials | Syneos Health | CPR Pharma Services","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"EP-7041","moa":"Coagulation factor XI (F11)","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"eXIthera Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"eXIthera Pharmaceutical \/ IDT CMAX Clinical Trials | Syneos Health | CPR Pharma Services","highestDevelopmentStatusID":"6","companyTruncated":"eXIthera Pharmaceutical \/ IDT CMAX Clinical Trials | Syneos Health | CPR Pharma Services"},{"orgOrder":0,"company":"ZetrOZ, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Diclofenac","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"ZetrOZ, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Patch","sponsorNew":"ZetrOZ, Inc. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ZetrOZ, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Daprodustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Ambit Biosciences | Kern Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Ambit Biosciences | Kern Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"Mayo Clinic \/ Ambit Biosciences | Kern Medical Center"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Kolon TissueGene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"TG-C","moa":"Transforming growth factor beta 1 (TGFB1)","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Kolon TissueGene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kolon TissueGene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kolon TissueGene \/ Undisclosed"},{"orgOrder":0,"company":"AnGes","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"AMG0103","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnGes \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AnGes \/ Undisclosed"},{"orgOrder":0,"company":"Red de Terapia Celular","sponsor":"Instituto Murciano de Investigaci\u00f3n Biosanitaria Virgen de la Arrixaca | Fundacion para la Formacion e Investigacion Sanitarias | Hospital Universitario Virgen de la Arrixaca | Spanish National Health System | Public Health Service, Murcia","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Autologous Bone Marrow Stem Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Red de Terapia Celular","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Red de Terapia Celular \/ Instituto Murciano de Investigaci\u00f3n Biosanitaria Virgen de la Arrixaca | Fundacion para la Formacion e Investigacion Sanitarias | Hospital Universitario Virgen de la Arrixaca | Spanish National Health System | Public Health Service, Murcia","highestDevelopmentStatusID":"6","companyTruncated":"Red de Terapia Celular \/ Instituto Murciano de Investigaci\u00f3n Biosanitaria Virgen de la Arrixaca | Fundacion para la Formacion e Investigacion Sanitarias | Hospital Universitario Virgen de la Arrixaca | Spanish National Health System | Public Health Service, Murcia"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Histogen","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HST003","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Histogen \/ US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Histogen \/ US Department of Defense"},{"orgOrder":0,"company":"Sclnow Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CHINA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Human Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Sclnow Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sclnow Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sclnow Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Children's Hospital of Philadelphia","sponsor":"Bracco | Pediatric Orthopaedic Society of North America","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Sulfur Hexafluoride","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Children's Hospital of Philadelphia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital of Philadelphia \/ Bracco | Pediatric Orthopaedic Society of North America","highestDevelopmentStatusID":"6","companyTruncated":"Children's Hospital of Philadelphia \/ Bracco | Pediatric Orthopaedic Society of North America"},{"orgOrder":0,"company":"BioTissue Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TTAX03","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"BioTissue Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioTissue Holdings \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioTissue Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Biosplice","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Lorecivivint","moa":"vinca alkaloids; WNT (wingless-type mouse mammary tumor virus) pathway inhibitors","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biosplice \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biosplice \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : SAR442501

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A First-in-human Single and Repeated Dose Escalation Study of SAR442501 in Healthy Adults Subjects

                            Details : SAR442501 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteochondrodysplasias.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            May 06, 2023

                            Lead Product(s) : SAR442501

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Biorestorative Therapies

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Biorestorative Therapies

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BRTX-100

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BioRestorative Gets FDA Clearance for BRTX-100 Phase 2 Trial

                            Details : BRTX-100 a novel cell-based therapeutic engineered to target areas of the body that have little blood flow. It is designed to offer a non-surgical treatment for chronic cervical discogenic pain.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            February 27, 2025

                            Lead Product(s) : BRTX-100

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BioTissue Holdings

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            BioTissue Holdings

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TTAX03

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TTAX03 for the Treatment of Lumbosacral Facet Joint Pain

                            Details : TTAX03 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Facet Joint Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 01, 2024

                            Lead Product(s) : TTAX03

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kolon TissueGene

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Kolon TissueGene

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TG-C

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Determine the Safety and Tolerability of TG-C in Subjects with Back Pain Due to Degenerative Disc Dis...

                            Details : TG-C is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Intervertebral Disc Degeneration.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            November 22, 2023

                            Lead Product(s) : TG-C

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Stayble Therapeutics

                            Sweden arrow
                            OTS 2025
                            Not Confirmed

                            Stayble Therapeutics

                            Sweden arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactic Acid

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase I

                            Sponsor : Cromsource | Antaros Medical | Viedoc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            STA363 in the Treatment of Lumbar Disc Herniation

                            Details : Lactic acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lumbar Disc Herniation.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 01, 2023

                            Lead Product(s) : Lactic Acid

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase I

                            Sponsor : Cromsource | Antaros Medical | Viedoc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ZetrOZ, Inc.

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            ZetrOZ, Inc.

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diclofenac

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Pain Related to Bone Fracture

                            Details : Diclofenac is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Fractures, Bone.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 31, 2023

                            Lead Product(s) : Diclofenac

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Histogen

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Histogen

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HST003

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase I

                            Sponsor : US Department of Defense

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Human ECM Implanted Within Microfracture Interstices & the Cartilage Defect in the Knee to Regenerate Hyaline ...

                            Details : HST003 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Knee Articular Cartilage Disorder.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 19, 2021

                            Lead Product(s) : HST003

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase I

                            Sponsor : US Department of Defense

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Northwell Health

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Northwell Health

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexamethasone

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Randomized Controlled Trial Assessing the Effect of Dexamethasone on Postoperative Function After Distal Radiu...

                            Details : Dexamethasone is a Steroid drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Wrist Fractures.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            May 17, 2021

                            Lead Product(s) : Dexamethasone

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Causeway Therapeutics

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Causeway Therapeutics

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tenomir

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability, and Pharmacokinetics of Single Dose TenoMiR as a Treatment for Tennis Elbow

                            Details : Tenomir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Tennis Elbow.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 17, 2020

                            Lead Product(s) : Tenomir

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sclnow Biotechnology

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Sclnow Biotechnology

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Umbilical Cord Mesenchymal Stem Cell

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Safety/Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-LDP) for Lumb...

                            Details : Human Umbilical Cord Mesenchymal Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lumbar Discogenic Pain.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 26, 2019

                            Lead Product(s) : Human Umbilical Cord Mesenchymal Stem Cell

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth